Citizens Jmp Increases Celcuity (NASDAQ:CELC) Price Target to $160.00

Celcuity (NASDAQ:CELC) had its target price upped by investment analysts at Citizens Jmp from $150.00 to $160.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s target price would indicate a potential upside of 9.29% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Monday, April 20th. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research note on Monday. Needham & Company LLC increased their target price on shares of Celcuity from $122.00 to $157.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Guggenheim increased their target price on shares of Celcuity from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.40.

Celcuity Stock Performance

Shares of CELC stock traded up $20.75 during trading on Monday, reaching $146.40. 1,156,078 shares of the company’s stock traded hands, compared to its average volume of 752,601. The company has a market capitalization of $7.08 billion, a P/E ratio of -38.69 and a beta of 0.09. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The firm’s 50-day moving average is $114.53 and its 200 day moving average is $102.64. Celcuity has a 1 year low of $9.51 and a 1 year high of $148.00.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. Equities research analysts expect that Celcuity will post -3.97 EPS for the current year.

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the sale, the director directly owned 6,760 shares in the company, valued at $745,425.20. This represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its holdings in shares of Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Celcuity in the 4th quarter worth $42,000. Ogorek Anthony Joseph NY ADV bought a new position in shares of Celcuity in the 3rd quarter worth $27,000. US Bancorp DE increased its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares during the last quarter. Finally, NBC Securities Inc. bought a new position in shares of Celcuity in the 4th quarter worth $99,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.